SELLAS Life Sciences (SLS) stock price is $11.98, up 14.20% on the day, as of Oct 20, 2026. It has a market cap of $2.26Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap2.26 Bn
P/E-69.62
P/S820.39
Div. Yield0.00
Revenue Growth (1y) (Qtr)276.47
Add ratio to table…
About
SELLAS Life Sciences Group, Inc. is a late stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
Its lead product candidates are galinpepimut S, a peptide immunotherapy that targets the Wilms tumor 1 antigen, and SLS009, a highly selective small molecule inhibitor of cyclin dependent kinase 9.
The company operates in the oncology biopharmaceutical sector aiming to bring these candidates through…
SELLAS Life Sciences Group, Inc. is a late stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Its lead product candidates are galinpepimut S, a peptide immunotherapy that targets the Wilms tumor 1 antigen, and SLS009, a highly selective small molecule inhibitor of cyclin dependent kinase 9. The company operates in the oncology biopharmaceutical sector aiming to bring these candidates through clinical development to potential marketing approval in the United States and other major markets.
SELLAS currently generates revenue principally through milestone and royalty payments received under its licensing and collaboration agreements as it has not yet commercialized any product. The company has received an upfront cash payment of $7.5 million and has earned additional milestone payments under its agreement with 3D Medicines for the development and commercialization of GPS in Greater China. As of December 31, 2025 the aggregate amount received from this agreement totaled $10.5 million. SELLAS may also receive royalties on net sales of GPS in Greater China if commercialization is achieved.
SELLAS positions itself as a developer of innovative immuno oncology and targeted small molecule therapies for acute myeloid leukemia and other hematologic and solid tumor indications. Its lead candidate GPS is distinguished by orphan drug designations from the FDA and the European Medicines Agency for acute myeloid leukemia malignant pleural mesothelioma and multiple myeloma as well as Fast Track designations for those indications. SLS009 has received orphan drug designation for acute myeloid leukemia and peripheral T cell lymphoma and Fast Track designation for relapsed or refractory acute myeloid leukemia and relapsed or refractory peripheral T cell lymphoma. Key competitors in the acute myeloid leukemia space include AbbVie and Genentech with venetoclax, Pfizer with gemtuzumab ozogamicin, Daiichi Sankyo with gilteritinib, Rigel Pharmaceuticals with vadastuximab talirine, Syndax Pharmaceuticals with entospletinib and Bristol Myers Squibb with azacitidine and decitabine. For SLS009 the competitive landscape includes other selective cyclin dependent kinase 9 inhibitors such as TP 1287 from Sumitomo Dainippon Pharma, zotiraciclib from Cothera Bioscience and PRT2527 from Prelude Therapeutics. SELLAS believes its competitive advantages lie in the novel mechanisms of action of its product candidates, the breadth of potential indications across more than twenty cancer types and the regulatory incentives that support faster development pathways.
SELLAS collaborates with several biopharmaceutical partners that provide funding, milestones or clinical trial support. Specific partners include 3D Medicines which licenses GPS for Greater China, Merck which co develops GPS in combination with pembrolizumab, Bristol Myers Squibb which provides nivolumab for combination studies in mesothelioma and GenFleet which licenses SLS009 for development outside Greater China.
Sector:HealthcareSector rationaleSELLAS Life Sciences is a clinical biopharmaceutical company developing therapeutics for cancer, specifically peptide immunotherapies and small molecule inhibitors. Its revenue is derived from licensing and collaboration agreements related to these medical product candidates, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector.Industries:BiotechnologyBiotechnologyPrimarySELLAS is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically galinpepimut S, a peptide immunotherapy. Its revenue is currently generated through milestone and royalty payments from collaboration agreements, such as the one with 3D Medicines.PharmaceuticalsPharmaceuticalsSecondaryIn addition to its peptide immunotherapy, the company is developing SLS009, which is described as a highly selective small molecule inhibitor of cyclin dependent kinase 9.Classified using BQ-MICSCIK: 0001390478
Bull & bear
Investment Thesis
▲ Bull case
SLS may be benefiting from structural shifts in consumer behavior and discretionary spending patterns that are not fully captured in short-term market sentiment, despite being flagged in a study as a potential laggard. The study identifying SLS as a stock likely to underperform relies on broad macroeconomic assumptions and historical correlations that may not account for company-specific initiatives such as supply chain optimization, digital transformation in retail channels, or niche product differentiation that could insulate it from sector-wide downturns. If SLS has been quietly investing in inventory management systems or expanding into underserved geographic markets, these moves could improve margins and sales velocity even amid broader economic uncertainty, creating a disconnect between pessimistic quantitative screens and actual operational resilience. Furthermore, if the company operates in a sub-sector with inelastic demand—such as essential household goods or budget-friendly alternatives—its revenue streams may prove more stable than the study’s model assumes, especially if consumers trade down during periods of inflation or rate volatility. The absence of a recent earnings call means management has not had the opportunity to articulate these countervailing strengths, leaving room for the market to overlook improving fundamentals that are not yet reflected in analyst estimates or price momentum. This gap between quantitative screening tools and qualitative business developments could create a scenario where SLS outperforms expectations if its underlying operations are stronger than the statistical model suggests.
SLS may be benefiting from structural shifts in consumer behavior and discretionary spending patterns that are not fully captured in short-term market sentiment, despite being flagged in a study as a potential laggard. The study identifying SLS as a stock likely to underperform relies on broad macroeconomic assumptions and historical correlations that may not account for company-specific initiatives such as supply chain optimization, digital transformation in retail channels, or niche product differentiation that could insulate it from sector-wide downturns. If SLS has been quietly investing in inventory management systems or expanding into underserved geographic markets, these moves could improve margins and sales velocity even amid broader economic uncertainty, creating a disconnect between pessimistic quantitative screens and actual operational resilience. Furthermore, if the company operates in a sub-sector with inelastic demand—such as essential household goods or budget-friendly alternatives—its revenue streams may prove more stable than the study’s model assumes, especially if consumers trade down during periods of inflation or rate volatility. The absence of a recent earnings call means management has not had the opportunity to articulate these countervailing strengths, leaving room for the market to overlook improving fundamentals that are not yet reflected in analyst estimates or price momentum. This gap between quantitative screening tools and qualitative business developments could create a scenario where SLS outperforms expectations if its underlying operations are stronger than the statistical model suggests.
SLS faces significant headwinds that the market may be underestimating, particularly if the study’s identification of it as a likely laggard reflects genuine vulnerabilities in its business model exposed by shifting macroeconomic conditions. The thesis that short sellers have favorable odds—even if geopolitical tensions ease, oil prices fall, or interest rates are cut—suggests that SLS’s underperformance is tied to structural weaknesses rather than temporary noise, such as declining same-store sales, aging product lines, or loss of market share to private-label or e-commerce competitors. If the company lacks pricing power or is over-reliant on promotional discounting to maintain volume, its margins could remain under pressure regardless of broader economic improvements, especially if input costs do not decline proportionally or if promotional intensity increases industry-wide. Furthermore, if SLS has delayed investments in omnichannel capabilities or digital marketing, it may continue to lose relevance among younger demographics, leading to a gradual erosion of brand equity that is not immediately visible in quarterly results but accumulates over time. The absence of a recent earnings call deprives investors of direct insight into management’s awareness of these issues or their credibility in addressing them, increasing the risk that problems are being overlooked or inadequately managed. Without clear signs of innovation, cost discipline, or market share stabilization, SLS could continue to deteriorate relative to peers, validating the study’s bearish outlook even in a more favorable macro environment.
SLS faces significant headwinds that the market may be underestimating, particularly if the study’s identification of it as a likely laggard reflects genuine vulnerabilities in its business model exposed by shifting macroeconomic conditions. The thesis that short sellers have favorable odds—even if geopolitical tensions ease, oil prices fall, or interest rates are cut—suggests that SLS’s underperformance is tied to structural weaknesses rather than temporary noise, such as declining same-store sales, aging product lines, or loss of market share to private-label or e-commerce competitors. If the company lacks pricing power or is over-reliant on promotional discounting to maintain volume, its margins could remain under pressure regardless of broader economic improvements, especially if input costs do not decline proportionally or if promotional intensity increases industry-wide. Furthermore, if SLS has delayed investments in omnichannel capabilities or digital marketing, it may continue to lose relevance among younger demographics, leading to a gradual erosion of brand equity that is not immediately visible in quarterly results but accumulates over time. The absence of a recent earnings call deprives investors of direct insight into management’s awareness of these issues or their credibility in addressing them, increasing the risk that problems are being overlooked or inadequately managed. Without clear signs of innovation, cost discipline, or market share stabilization, SLS could continue to deteriorate relative to peers, validating the study’s bearish outlook even in a more favorable macro environment.